In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, ATAI Life Sciences N.V’s stock clocked out at $1.61, up 5.92% from its previous closing price of $1.52. In other words, the price has increased by $5.92 from its previous closing price. On the day, 2.09 million shares were traded. ATAI stock price reached its highest trading level at $1.71 during the session, while it also had its lowest trading level at $1.42.
Ratios:
To gain a deeper understanding of ATAI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.81 and its Current Ratio is at 5.81. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on November 18, 2024, Reiterated its Buy rating but revised its target price to $10 from $15 previously.
On April 03, 2024, Maxim Group Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $6.
On November 01, 2022, Loop Capital started tracking the stock assigning a Buy rating and target price of $18.Loop Capital initiated its Buy rating on November 01, 2022, with a $18 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 26 ’24 when ATAI Life Sciences N.V. sold 2,660,000 shares for $6.05 per share. The transaction valued at 16,093,000 led to the insider holds 6,905,774 shares of the business.
Brand Florian sold 151,303 shares of ATAI for $290,502 on May 16 ’24. The insider now owns 328,697 shares after completing the transaction at $1.92 per share. On Apr 02 ’24, another insider, Johnson Anne Nagengast, who serves as the Chief Financial Officer of the company, sold 27,410 shares for $1.85 each. As a result, the insider received 50,708 and left with 73,590 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATAI now has a Market Capitalization of 270161216 and an Enterprise Value of 197084128. For the stock, the TTM Price-to-Sale (P/S) ratio is 867.14 while its Price-to-Book (P/B) ratio in mrq is 1.85. Its current Enterprise Value per Revenue stands at 595.42 whereas that against EBITDA is -1.924.
Stock Price History:
Over the past 52 weeks, ATAI has reached a high of $2.85, while it has fallen to a 52-week low of $1.02. The 50-Day Moving Average of the stock is 29.11%, while the 200-Day Moving Average is calculated to be 3.50%.
Shares Statistics:
It appears that ATAI traded 1.07M shares on average per day over the past three months and 3207970 shares per day over the past ten days. A total of 166.03M shares are outstanding, with a floating share count of 117.06M. Insiders hold about 30.24% of the company’s shares, while institutions hold 7.17% stake in the company. Shares short for ATAI as of 1730332800 were 9428027 with a Short Ratio of 8.81, compared to 1727654400 on 9484569. Therefore, it implies a Short% of Shares Outstanding of 9428027 and a Short% of Float of 7.359999999999999.
